Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025” report to its portfolio. The study provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of Immune Checkpoint Inhibitors (ICIs).
Rupali Verma, the principal analyst, said, “The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were pioneers in this segment. Yervoy was the only immunotherapeutic commercially available until other classes stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost. In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which are expected to gain traction in the future.”
Verma further stated, “The market is currently characterized by the presence of three marketed drugs and 34 drugs in clinical development.
BMS, with ten ICIs, is the leading player followed by other giants including AstraZeneca, Merck, Pfizer, Roche, GSK, Novartis and Amgen.
Several molecules are being tested in combination with other drug classes; Jan 2014-May 2015 saw over 40 such collaborations.”